Lilly to Acquire Novartis Animal Health - - BioPharm International

ADVERTISEMENT

Lilly to Acquire Novartis Animal Health



Eli Lilly and Company will acquire Novartis Animal Health for approximately $5.4 billion in an all-cash transaction that will expand Lilly's animal health business, Elanco. Upon completion of the acquisition,Elanco will be the second-largest animal health company in terms of global revenue. Lilly will acquire Novartis Animal Health's nine manufacturing sites, six research and development facilities, a portfolio of approximately 600 products, a pipeline with more than 40 projects in development, and over 3000 employees.

Lilly plans to fund this acquisition with approximately $3.4 billion of cash-on-hand and $2 billion in debt to be issued. No other financial terms of the transaction are being disclosed. The transaction is expected to close by the end of the first quarter of 2015, subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, similar requirements outside the US, and other customary closing conditions. The transaction is not subject to any financing conditions.

With this acquisition, Lilly expects to save an estimated $200 million per year within the first three years of the deal closing, adding up to more than 10% of operating expenses from the combined animal health businesses.

The acquisition will expand Elanco's product portfolio, R&D and manufacturing capabilities, and commercial presence. In addition, Elanco will have a greater presence in the animal and swine markets, the equine and vaccines areas, and the aquaculture market.

Source: Eli Lilly and Company

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines

Click here